Top

Published in:

01-08-2006 | Educational Review

Surgical Adjuvant Therapy for Colorectal Cancer: Current Approaches and Future Directions

Authors: Dulabh K. Monga, MD, Michael J. O’Connell, MD

Published in: Annals of Surgical Oncology | Issue 8/2006

Abstract

Colon cancer is the fourth most common cancer worldwide. The role of systemic adjuvant chemotherapy in colorectal cancer patients with lymph node involvement has been established in a large number of clinical trials. However, its role in stage II colorectal cancer is less well established. 5-Fluorouracil has been the mainstay of therapy for the last four decades. With the development of novel chemotherapy and biological agents, we have entered into a new era for the treatment of colorectal cancer. The combination of adjuvant 5-fluorouracil, leucovorin, and oxaliplatin has been shown to significantly improve disease-free survival and is now considered the standard of care for completely resected colon cancer in healthy patients. For rectal cancer patients with locally advanced tumors, neoadjuvant chemoradiation followed by adjuvant chemotherapy after surgery is the mainstay of treatment. The availability of oral chemotherapy agents has helped with the ease of administration and avoidance of indwelling catheters. A number of national clinical trials are under way to determine the role of targeted agents in combination with chemotherapy. The goal is to develop a regimen that would improve survival without excessive toxicity while maintaining quality of life. Patients should be encouraged to participate in clinical trials whenever feasible. Despite the advances, many patients will develop recurrent disease. It is of utmost importance to develop molecular markers that could predict which patients are at high risk for disease recurrence. Clinical trials are under way to address this issue. Thus, it will be advantageous to be able to tailor therapy individually, according to the risk of recurrence.

Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10–30PubMedCrossRef

Makela J, Haukipuro K, Laitinen S, Kairaluoma MI. Surgical treatment of recurrent colorectal cancer. Five-year follow-up. Arch Surg 1989; 124:1029–32PubMed

Olson RM, Perencevich NP, Malcolm AW, et al. Patterns of recurrence following curative resection of adenocarcinoma of the colon and rectum. Cancer 1980; 45:2969–74PubMedCrossRef

Colon and rectum. American Joint Commitee on Cancer, AJCC Cancer staging Manual. 6^thed. New York, NY: Springer, 2002:113–24

MacDonald JS. Adjuvant therapy of colon cancer. CA Cancer J Clin 1999; 113–9

Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22:1797–806PubMedCrossRef

Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17:1349–55PubMed

Gray RG, Barnwell J, Hills R, et al. QUASAR: a randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients (abstract). Proc Am Soc Clin Oncol 2004; 22(14 Suppl):3501

Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309–18; discussion 318–21PubMedCrossRef

10.

Nordlinger B, Vaillant JC, Guiguet M, et al. Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol 1994; 12:1491–6PubMed

11.

Tepper JE, O’Connell MJ, Petroni GR, et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol 1997; 15:2030–9PubMed

12.

Poon MA, O’Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7:1407–18PubMed

13.

NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264:1444–50CrossRef

14.

Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322:352–8PubMedCrossRef

15.

Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122:321–6PubMed

16.

O’Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15:246–50PubMed

17.

Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11:1879–87PubMed

18.

O’Connell MJ, Wolmark N, Yothers G, et al. Durable improvement in disease free survival (DFS) and overall survival (OS) for stage II or III colon cancer treated with leucovorin modulated fluorouracil (FL): 10-year followup of National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol C-03 (abstract). Proc Am Soc Clin Oncol 2005; 23(16 Suppl):3511

19.

Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345:939–44CrossRef

20.

O’Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16:295–300PubMed

21.

Haller DG, Lefkopoulou M, Macdonald JS, Mayer RS. Some considerations concerning the dose and schedule of 5FU and leucovorin: toxicities of two dose schedules from the intergroup colon adjuvant trial (INT-0089). Adv Exp Med Biol 1993; 339:51–4; discussion 55–6PubMed

22.

Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17:3553–9PubMed

23.

Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343–51PubMedCrossRef

24.

de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median followup of 4 years (abstract). Proc Am Soc Clin Oncol 2005; 23(16 Suppl):3501

25.

Wolmark N, Wieand HS, Kuebler JP, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07 (abstract). Proc Am Soc Clin Oncol 2005; 23(16 Suppl):LBA3500

26.

Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201–8PubMedCrossRef

27.

Van Cutsem E, Labianca R, Hossfeld D, et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts) (PETACC 3) (abstract). Proc Am Soc Clin Oncol 2005; 23(16 Suppl):LBA-8

28.

Ychou M, Raoul JL, Douillard JY, et al. Phase III randomized trial of LV5FU2 plus CPT-11 versus LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802) (abstract). Proc Am Soc Clin Oncol 2005; 23(16 Suppl):3502

29.

Cassidy J, Scheithauer W, McKendrick J, et al. Capecitabine (X) versus bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (X-ACT study): positive efficacy results of a phase III trial (abstract). Proc Am Soc Clin Oncol 2004; 22(14 Suppl):3509

30.

Twelves C, Wong A, Nowacki MP, et al. Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) versus bolus 5-FU/LV as adjuvant therapy for patients with Duke’s C colon cancer (abstract). Proc Am Soc Clin Oncol 2005; 23(16 Suppl):3521

31.

Wolmark N, Wieand HS, Lambersky B, et al. A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: results of NSABP protocol C-06 (abstract). Proc Am Soc Clin Oncol 2004; 22(14 Suppl):3508

32.

Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999; 17:1356–63

33.

Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol 2004; 22:3395–407PubMedCrossRef

34.

Figueredo A, Germond C, Maroun J, et al. Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group. Cancer Prev Control 1997; 1:379–92PubMed

35.

Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22:3408–19PubMedCrossRef

36.

Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335–42PubMedCrossRef

37.

Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337–45PubMedCrossRef

38.

Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988; 80:21–9PubMed

39.

Minsky BD, Mies C, Recht A, et al. Resectable adenocarcinoma of the rectosigmoid and rectum. I. Patterns of failure and survival. Cancer 1988; 61:1408–16PubMedCrossRef

40.

Rich T, Gunderson LL, Lew R, et al. Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer 1983; 52:1317–29PubMedCrossRef

41.

Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med 1985; 312:1465–72CrossRef

42.

Wolmark N, Wieand HS, Hyams DM, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 2000; 92:388–96PubMedCrossRef

43.

O’Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331:502–7PubMedCrossRef

44.

Tepper JE, O’Connell M, Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control—final report of intergroup 0114. J Clin Oncol 2002; 20:1744–50PubMedCrossRef

45.

Smalley SR, Benedetti J, Williamson S. Intergroup 0144-phase III trial of 5-FU based chemotherapy regimen plus radiotherapy (XRT) in postoperative adjuvant rectal cancer: bolus 5-FU versus prolonged venous infusion (PVI) before and after XRT plus PVI versus bolus 5-FU plus leucovorin (LV) plus levamisole (lev) before and after XRT plus bolus 5-FU plus LV (abstract). Proc Am Soc Clin Oncol 2003; 22:1006

46.

Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986; 2:996–9PubMedCrossRef

47.

Marks G, Mohiuddin M, Rakinic J. New hope and promise for sphincter preservation in the management of cancer of the rectum. Semin Oncol 1991; 18:388–98PubMed

48.

Hansen E, Wolff N, Knuechel R, et al. Tumor cells in blood shed from the surgical field. Arch Surg 1995; 130:387–93PubMed

49.

Pahlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. Ann Surg 1990; 211:187–95PubMedCrossRef

50.

Camma C, Giunta M, Fiorica F, et al. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 2000; 284:1008–15PubMedCrossRef

51.

Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345:638–46PubMedCrossRef

52.

Kapiteijn E, van de Velde CJ. Developments and quality assurance in rectal cancer surgery. Eur J Cancer 2002; 38:919–36PubMedCrossRef

53.

Chari RS, Tyler DS, Anscher MS, et al. Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg 1995; 221:778–86; discussion 786–7PubMed

54.

Mendenhall WM, Bland KI, Copeland EM III, et al. Does preoperative radiation therapy enhance the probability of local control and survival in high-risk distal rectal cancer? Ann Surg 1992; 215:696–705; discussion 705–6PubMed

55.

Minsky BD, Cohen AM, Kemeny N, et al. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol 1992; 10:79–84PubMed

56.

Rich TA, Skibber JM, Ajani JA, et al. Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys 1995; 32:1025–9PubMedCrossRef

57.

Bosset JF, Mantion G, Lorchel F, et al. Adjuvant and neoadjuvant radiation therapy for rectal cancer. Semin Oncol 2000; 27(5 Suppl 10):60–5PubMed

58.

Mohiuddin M, Regine WF, Marks GJ, Marks JW. High-dose preoperative radiation and the challenge of sphincter-preservation surgery for cancer of the distal 2 cm of the rectum. Int J Radiat Oncol Biol Phys 1998; 40:569–74PubMedCrossRef

59.

Wagman R, Minsky BD, Cohen AM, et al. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys 1998; 42:51–7PubMedCrossRef

60.

Hyams DM, Mamounas EP, Petrelli N, et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum 1997; 40:131–9PubMedCrossRef

61.

Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731–40PubMedCrossRef

62.

Jessup JM, McGinnis LS, Steele GD Jr, et al. The National Cancer Data Base. Report on colon cancer. Cancer 1996; 78:918–26PubMedCrossRef

63.

Dizon DS, Kemeny NE. Intrahepatic arterial infusion of chemotherapy: clinical results. Semin Oncol 2002; 29:126–35PubMedCrossRef

64.

Adson MA, van Heerden JA, Adson MH, et al. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984; 119:647–51PubMed

65.

Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235:759–66PubMedCrossRef

66.

Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77:1254–62PubMedCrossRef

67.

Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039–48PubMedCrossRef

68.

Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy—an intergroup study. J Clin Oncol 2002; 20:1499–505PubMedCrossRef

69.

Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8:347–53PubMed

70.

Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224:509–20; discussion 520–2PubMedCrossRef

71.

Falcone A, Masi G, Allegrini G, et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002; 20:4006–14PubMedCrossRef

72.

Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10:663–9PubMedCrossRef

73.

Tabernero J, Van Cutsem E, J. S, et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil/folinic acid (FOLFOX4) in the first line treatment of patients with metastatic colorectal cancer expressing epidermal growth factor receptor. Preliminary results (abstract). Proc Am Soc Clin Oncol 2004; 22(14 Suppl):3512

74.

Alberts SR, Donohue JH, Mahoney MR, et al. Liver resection after 5-FU, leucovorin and oxaliplatin for patients with metastatic colorectal cancer limited to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study (abstract). Proc Am Soc Clin Oncol 2003; 22:1053

Title: Surgical Adjuvant Therapy for Colorectal Cancer: Current Approaches and Future Directions
Authors: Dulabh K. Monga, MD
Michael J. O’Connell, MD
Publication date: 01-08-2006
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 8/2006
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/ASO.2006.08.015

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Surgical Adjuvant Therapy for Colorectal Cancer: Current Approaches and Future Directions

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2006

Prognostic Significance of Vascular Endothelial Growth Factor Expression and Microvessel Density in Esophageal Squamous Cell Carcinoma: Comparison With Positron Emission Tomography

Sentinel Lymph Node Biopsy for Local Recurrence of Breast Cancer After Breast-Conserving Therapy

Surgery and Hematogenous Dissemination: Comparison Between the Detection of Circulating Tumor Cells and of Tumor DNA in Plasma Before and After Tumor Resection in Rats

Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy

Pilot Study of Oncolytic Viral Therapy Using Mutant Herpes Simplex Virus (HF10) Against Recurrent Metastatic Breast Cancer

A Phase II Trial of Isolated Limb Infusion With Melphalan and Dactinomycin for Regional Melanoma and Soft Tissue Sarcoma of the Extremity